Valproic acid defines a novel class of HDAC inhibitors inducing differentiation of transformed cells

EMBO Journal

Volumn 20, Issue 24, 2001, Pages 6969-6978

  Göttlicher, Martin ^a   Minucci, Saverio ^b   Zhu, Ping ^a   Krämer, Oliver H ^c   Schimpf, Annemarie ^c   Giavara, Sabrina ^b   Sleeman, Jonathan P ^a   Lo Coco, Francesco ^d   Nervi, Clara ^d   Pelicci, Pier Giuseppe ^b   Heinzel, Thorsten ^c  

^a KARLSRUHE INSTITUTE OF TECHNOLOGY   (Germany)

^b INSTITUTE FOR TUMOR BIOLOGY AND EXPERIMENTAL THERAPY   (Germany)

^c EUROPEAN INSTITUTE OF ONCOLOGY   (Italy)

^d SAPIENZA UNIVERSITY OF ROME   (Italy)

Author keywords

Cancer therapy; HDAC inhibitor; Histone deacetylase; Leukemia; Valproic acid

Indexed keywords

HISTONE DEACETYLASE; SODIUM CHLORIDE; VALPROIC ACID;

ACETYLATION; ACUTE GRANULOCYTIC LEUKEMIA; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER; CANCER CELL CULTURE; CANCER GROWTH; CARCINOGENESIS; CELL DIFFERENTIATION; CELL TRANSFORMATION; CONTROLLED STUDY; DRUG MECHANISM; HEMATOPOIETIC STEM CELL; HUMAN; HUMAN CELL; METASTASIS; NONHUMAN; PRIORITY JOURNAL; RAT; TRANSCRIPTION REGULATION;

ANIMALS; CELL DIFFERENTIATION; CELL LINE, TRANSFORMED; CRICETINAE; ENZYME INHIBITORS; HISTONE DEACETYLASES; HUMANS; RECEPTORS, CYTOPLASMIC AND NUCLEAR; RECEPTORS, GLUCOCORTICOID; TRANSCRIPTION FACTORS; TRANSCRIPTION, GENETIC; VALPROIC ACID;

ANIMALIA;

EID: 18244383806     PISSN: 02614189     EISSN: None     Source Type: Journal    
DOI: 10.1093/emboj/20.24.6969     Document Type: Article

References (49)

1. Role for N-CoR and histone deacetylase in Sin3-mediated transcriptional repression
2. Suberoylanilide hydroxamic acid, an inhibitor of histone deacetylase, suppresses the growth of prostate cancer cells in vitro and in vivo
3. A transcriptional co-repressor that interacts with nuclear hormone receptors
4. Altered ligand binding and transcriptional regulation by mutations in the PML/RARα ligand-binding domain arising in retinoic acid-resistant patients with acute promyelocytic leukemia
5. Identification of a retinoic acid responsive element in the retinoic acid receptor β gene
6. The LAZ3(BCL-6) oncoprotein recruits a SMRT/mSIN3A/histone deacetylase containing complex to mediate transcriptional repression
7. The fetal valproate syndrome
8. A mouse model for valproate teratogenicity: Parental effects, homeotic transformations and altered HOX expression
9. Histone deacetylase-targeted treatment restores retinoic acid signaling and differentiation in acute myeloid leukemia
10. Structures of a histone deacetylase homologue bound to the TSA and SAHA inhibitors
11. Aberrant recruitment of the nuclear receptor corepressor-histone deacetylase complex by the acute myeloid leukemia fusion partner ETO
12. The coregulator exchange in transcriptional functions of nuclear receptors
13. Fatty acids activate a chimera of the clofibric acid-activated receptor and the glucocorticoid receptor
14. Fusion proteins of the retinoic acid receptor-α recruit HDAC in promyelocytic leukaemia
15. Reduced retinoic acid-sensitivities of nuclear receptor corepressor binding to PML- and PLZF-RARα underlie molecular pathogenesis and treatment of acute promyelocytic leukemia
16. Asymmetric synthesis and teratogenic activity of (R)- and (S)-2-ethylhexanoic acid, a metabolite of the plasticizer di-(2-ethylhexyl)phthalate
17. Distinct interactions of PML-RARα and PLZF-RARα with co-repressors determine differential responses to RA in APL
18. PPARδ is an APC-regulated target of nonsteroidal anti-inflammatory drugs
19. A complex containing N-CoR, mSin3 and histone deacetylase mediates transcriptional repression
20. Enhancement of peroxisomal β-oxidation in the liver of rats and mice treated with valproic acid
21. Ligand-independent repression by the thyroid hormone receptor mediated by a nuclear receptor co-repressor
22. Roles of PPARs in health and disease
23. Hematopoietic cytokine-dependent differentiation to eosinophils and neutrophils in a newly established acute promyelocytic leukemia cell line with t(15;17)
24. Differential expression and activation of a family of murine peroxisome proliferator-activated receptors
25. Histone deacetylase as a therapeutic target
26. Histone deacetylases associated with the mSin3 corepressor mediate mad transcriptional repression
27. New molecular bioassays for the estimation of the teratogenic potency of valproic acid derivatives in vitro: Activation of the peroxisomal proliferator-activated receptor (PPARδ)
28. Role of the histone deacetylase complex in acute promyelocytic leukaemia
29. Valproate: A reappraisal of its pharmacodynamic properties and mechanisms of action
30. Pharmacological evaluation of various metabolites and analogues of valproic acid. Anticonvulsant and toxic potencies in mice
31. ETO, a target of t(8;21) in acute leukemia, interacts with the N-CoR and mSin3 corepressors
32. Enantioselectivity in the induction of peroxisome proliferation by 2-ethylhexanoic acid
33. Activation of MHC class I, II and CD40 gene expression by HDAC inhibitors
34. Histone deacetylase inhibitors: Inducers of differentiation or apoptosis of transformed cells
35. Oligomerization of RAR and AML1 transcription factors as a novel mechanism of oncogenic activation
36. Histone deacetylases: A common molecular target for differentiation treatment of acute myeloid leukemias?
37. Nuclear receptor repression mediated by a complex containing SMRT, mSin3A and histone deacetylase
38. Valproic acid-induced neural tube defects in mouse and human: Aspects of chirality, alternative drug development, pharmacokinetics and possible mechanisms
39. Butyrate and phenylacetate as differentiating agents: Practical problems and opportunities
40. Histone deacetylase is a direct target of valproic acid, a potent anticonvulsant, mood stabilizer and teratogen
41. Valnoctamide, valpromide and valnoctic acid are much less teratogenic in mice than valproic acid
42. Cytochrome P-450-catalyzed formation of δ 4-VPA, a toxic metabolite of valproic acid
43. The language of covalent histone modifications
44. The expression of a small fraction of cellular genes is changed in response to histone hyperacetylation
45. ETO, fusion partner in t(8;21) acute myeloid leukemia, represses transcription by interaction with the human N-CoR/mSin3/HDACI complex
46. Therapeutic targeting of transcription in acute promyelocytic leukemia by use of an inhibitor of histone deacetylase
47. Induction of differentiation in F9 cells and activation of peroxisome proliferator-activated receptor δ by valproic acid and its teratogenic derivatives
48. Coactivator and corepressor complexes in nuclear receptor function
49. Trichostatin A and trapoxin: Novel chemical probes for the role of histone acetylation in chromatin structure and function